Every piece MicroCap Desk has published on Cardiff Oncology, newest first. Independent editorial — we take no compensation from the companies we cover.
Cardiff Oncology showed Phase 2 onvansertib data at ASCO and picked a 30mg dose for a planned Phase 3 in colon cancer.
The biology behind KRAS-mutated colorectal cancer and how investors should read the trial data.
Sentiment labels reflect the Desk's directional view at the time each article was published and are not price targets, ratings, or investment advice. Microcap securities carry a high risk of loss. See our full Disclosure.